UBS Group
SCMP

UBS Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

UBS Group’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-263,403
Closed -$4.73M – 8517
2017
Q4 		$4.73M Buy
263,403
+224,460
+576% +$2.76M ﹤0.01% 2405
2017
Q3 		$460K Buy
38,943
+12,619
+48% +$142K ﹤0.01% 4274
2017
Q2 		$276K Sell
26,324
-4,445
-14% -$45.3K ﹤0.01% 4540
2017
Q1 		$339K Sell
30,769
-21,847
-42% -$254K ﹤0.01% 4303
2016
Q4 		$713K Buy
52,616
+22,749
+76% +$317K ﹤0.01% 3851
2016
Q3 		$368K Buy
29,867
+25,900
+653% +$305K ﹤0.01% 4127
2016
Q2 		$44K Buy
3,967
+2,351
+145% +$26.3K ﹤0.01% 5620
2016
Q1 		$18K Sell
1,616
-1,294
-44% -$16.4K ﹤0.01% 6303
2015
Q4 		$50K Sell
2,910
-10,756
-79% -$193K ﹤0.01% 5825
2015
Q3 		$271K Buy
13,666
+12,750
+1,392% +$292K ﹤0.01% 4396
2015
Q2 		$15K Hold
916
– – ﹤0.01% 7148
2015
Q1 		$14K Buy
916
+280
+44% +$4.34K ﹤0.01% 7387
2014
Q4 		$9K Buy
+636
New +$6.72K ﹤0.01% 8524

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

UBS Group's SCMP Position: Q1 2018 in Review

UBS Group sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 263,403 shares — an estimated $4.73M sold.

UBS Group first reported a position in SCMP in Q4 2014 and held it in 13 quarters. The position peaked at $4.73M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • UBS Group reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 263,403 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $4.73M.
  • UBS Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2014 and held it in 13 quarters.
  • UBS Group's Sucampo Pharmaceuticals, Inc. position peaked at $4.73M in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.